CTI OPAXIO™ Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Published: Tuesday, October 09, 2012 Last Updated: Monday, October 08, 2012
Randomized front line trial utilizing tumor genomic profiling tests OPAXIO plus radiation therapy compared to current standard of care of radiation with temozolamide in high risk patients with glioblastoma multiforme.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.